CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-581.6	-366.25	-153.61	-650.18	377.66
Depreciation & Amortization	19.48	19.26	19.84	24.17	17.95
Asset Writedown & Restructuring Costs	96.25	-	2.5	-	-
Stock-Based Compensation	72.5	86.57	81.03	97.95	102.39
Other Operating Activities	-23.53	-38.62	-16.55	12.47	14.11
Change in Accounts Receivable	25	175	-200	0.31	-0.16
Change in Accounts Payable	44.89	-27.28	-20.25	5.16	37.51
Change in Unearned Revenue	-0.4	-1.95	5.79	-1.01	-0.78
Change in Other Net Operating Assets	2.39	10.5	20.87	15.39	-9.71
Operating Cash Flow	-345.01	-142.77	-260.38	-495.74	538.97
Capital Expenditures	-0.91	-1.9	-9.47	-37.19	-81.71
Sale (Purchase) of Intangibles	-25	-	-2.5	-	-
Investment in Securities	-5.89	-278.58	386.62	-221.47	-953.73
Investing Cash Flow	-31.81	-280.48	374.65	-258.66	-1,035
Issuance of Common Stock	426.03	331.98	62.66	38.59	250.95
Financing Cash Flow	426.03	331.98	62.66	38.59	250.95
Foreign Exchange Rate Adjustments	0.1	-0.02	0.07	-0.08	-0.01
Miscellaneous Cash Flow Adjustments	-	-	-0	-	-
Net Cash Flow	49.3	-91.29	177.01	-715.88	-245.52
Free Cash Flow	-345.93	-144.68	-269.85	-532.93	457.27
Free Cash Flow Margin	-9855.50%	-387.72%	-72.69%	-44484.89%	49.98%
Free Cash Flow Per Share	-3.85	-1.72	-3.41	-6.86	5.69
Levered Free Cash Flow	-205.62	-29.27	-238.97	-337.58	284.82
Unlevered Free Cash Flow	-205.62	-29.27	-238.97	-337.58	284.82
Change in Working Capital	71.88	156.27	-193.59	19.85	26.86

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q